research Treatment of intralesional corticoisteroid-induced cutaneous atrophy with hyaluronic acid filling
Hyaluronic acid successfully treated skin atrophy caused by corticosteroid injections.
Search
for
Sort by
Research
240-270 / 1000+ results research Baricitinib Provides Higher Efficacy in Adolescents Relative to Adults With Alopecia Areata Despite More Severe Disease at Baseline: 36-Week Outcomes From BRAVE-AA Trials
The study found that Baricitinib (Bari), a Janus kinase inhibitor, is effective and safe for treating severe alopecia areata (AA) in both adolescents and adults. In the BRAVE-AA trials, 257 adolescents and 1,200 adults were treated with either Bari 4mg, Bari 2mg, or a placebo. At 36 weeks, 42.4% of adolescents on Bari 4mg achieved a SALT score of less than 20, compared to 34% of adults. Adolescents showed higher response rates despite having more severe disease at baseline, indicating the potential benefits of early intervention. Common side effects included headache, acne, and upper respiratory tract infections.
research Perilymphatic Atrophy of the Skin
Corticosteroid injections for hair loss can cause skin thinning.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research Gut instinct: Using tofacitinib to treat alopecia areata in the context of comorbid inflammatory bowel disease
Tofacitinib may help treat both alopecia areata and inflammatory bowel disease.
research Title Choice of treatment for severe forms of alopecia areata (case reports)
JAK inhibitors like tofacitinib are effective and safer for severe alopecia areata than glucocorticosteroids.
research Efficacy and safety of deuruxolitinib, an oral selective Janus kinase inhibitor, in adults with alopecia areata: Results from the Phase 3 randomized, controlled trial (THRIVE-AA1)
Deuruxolitinib effectively promotes hair regrowth in adults with alopecia areata.
research Alopecia areata
Baricitinib shows promise for severe alopecia areata but isn't a cure and has side effects.
research FDA declines approval of testosterone drug for third time
The FDA rejected a testosterone drug again due to safety concerns.
research 51840 Efficacy of the Oral JAK1/JAK2 Inhibitor Deuruxolitinib in Adult Patients with Moderate to Severe Alopecia Areata: Pooled Results from the Multinational Double-Blind, Placebo-Controlled THRIVE-AA1 and THRIVE-AA2 Phase 3 Trials
Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.
research Pulse Corticosteroid Therapy for Alopecia Areata in Children: A Retrospective Study
Careful patient selection is key for effective pulse corticosteroid treatment in children with alopecia areata.
research Systemic Steroids With or Without 2% Topical Minoxidil in the Treatment of Alopecia Areata
Steroids help hair regrowth, and minoxidil slows post-steroid hair loss, but effects are temporary.
research Diffuse plate-like sheets of desquamation
The rash resolved after stopping ponatinib.
research Successful treatment of severe atopic dermatitis and alopecia universalis with upadacitinib in a 29-year-old male patient
Upadacitinib effectively improved severe atopic dermatitis and alopecia universalis in a 29-year-old man.
research Combination therapy of alopecia areata using cyclosporine and low-dose corticosteroid: A long-term follow-up study
Combination therapy with cyclosporine and low-dose corticosteroid shows favorable long-term results for treating alopecia areata.
research A CLINICAL STUDY OF ALOPECIA AREATA AND TO EVALUAT E OF THE EFFICACY OF 0.03% TOPICAL TACROLIMUS IN ITS TREATMENT
Topical tacrolimus is effective and safe for treating alopecia areata.
research Efficacy and Safety of Methotrexate Combined with Low- to Moderate-Dose Corticosteroids for Severe Alopecia Areata
Methotrexate with corticosteroids can effectively treat severe alopecia areata but often requires long-term maintenance.
research ORAL TOFACITINIB IN MODERATE AND SEVERE ALOPECIA AREATA: CASE SERIES OF 14 PATIENTS
Tofacitinib helped regrow hair in most patients with severe hair loss.
research Dermatologic therapy: December 1986 to December 1987
Various dermatologic treatments were effective for skin conditions like acne, rosacea, hair loss, and psoriasis from December 1986 to December 1987.
research COMPARISON OF EFFECTIVENESS OF TOPICAL TACROLIMUS AND BETAMETHASONE WITH SOFT PARAFFIN IN THE TREATMENT OF PATCHY ALOPECIA AREATA
Betamethasone is more effective than Tacrolimus and soft paraffin for hair regrowth in patchy alopecia areata.
research Treatment of an alopecia areata patient with tofacitinib results in regrowth of hair and changes in serum and skin biomarkers
A patient with alopecia areata regrew hair after taking tofacitinib and showed changes in certain blood and skin markers.
research Phosphodiesterase inhibitors and prostaglandin analogues in dermatology: A comprehensive review
Certain drugs are effective for skin conditions like psoriasis, vitiligo, and hair loss.
research Treatment of resistant alopecia areata with tofacitinib
Tofacitinib may be effective for treating hair loss caused by alopecia areata that doesn't respond to other treatments.
research Medical Therapies
Combination therapies might work better for some vitiligo patients, but results vary.
research Excellent response to tofacitinib treatment in a patient with alopecia universalis
A patient with complete hair loss regrew all her hair using tofacitinib.
research Simultaneous improvement of alopecia universalis and atopic dermatitis in a patient treated with a JAK inhibitor
A JAK inhibitor improved both severe hair loss and chronic skin disease in one patient.
research CUTANEOUS T-CELL LYMPHOMA
The document concludes that DAB389-IL2 is promising for treating refractory cutaneous T-cell lymphoma, but more research is needed on its effectiveness and side effect management.
research FORMULATION AND EVALUATION OF A TOPICAL GEL CONTAINING MINOXIDIL AND TOFACITINIB CITRATE FOR ALOPECIA AREATA
The formulated gel is a promising treatment for alopecia areata.
![Discovery of 7-Methoxy-6-[4-(4-Methyl-1,3-Thiazol-2-yl)-1H-Imidazol-5-yl]-1,3-Benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia](/images/research/9620bd26-3366-4f2a-bcac-f511697bbc41/small/35997.jpg)
research Discovery of 7-Methoxy-6-[4-(4-methyl-1,3-thiazol-2-yl)-1H-imidazol-5-yl]-1,3-benzothiazole (TASP0382088): A Potent and Selective Transforming Growth Factor-β Type I Receptor Inhibitor as a Topical Drug for Alopecia
A new compound shows promise as a topical treatment for hair loss.
research LB1056 Phase 1b: Translational evaluation of VYN201, a pan-BD BET inhibitor, for the treatment of non-segmental vitiligo
VYN201 shows promise as a safe and effective treatment for non-segmental vitiligo.